Article Text

PDF
▼ Daclizumab for MS

Abstract

▼Daclizumab (Zinbryta—Biogen Idec) is a new injectable disease-modifying drug licensed for the treatment of relapsing forms of multiple sclerosis (MS) in adults.1 It is a humanised monoclonal antibody that modulates interleukin-2 signalling.1-3 Here, we review the evidence on daclizumab and consider its place in the management of MS.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.